Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

RIC in Patients with FL Receiving Allo-HCT

Biol Blood Marrow Transplant; ePub 2017 Oct 13; Epperla, et al

Reduced-intensity conditioning with either of 2 drug combinations leads to superior survival and acceptable non-relapse mortality in patients with follicular lymphoma undergoing allogeneic hematopoietic cell transplantation (allo-HCT), according to a study involving 200 individuals. 1 of the regimens was linked with lower chronic graft-versus-host disease (GVHD).

Participants were given either fludarabine and busulfan (Flu/Bu; n=98) or fludarabine, cyclophosphamide, and rituximab (FCR; n=102) between 2008 and 2014. They also received peripheral blood grafts, as well as calcineurin inhibitors for GVHD prophylaxis. Among the results:

  • 3-year non-relapse mortality, relapse/progression, progression-free survival, and overall survival rates were similar in both groups.
  • There were also no differences in grade II-IV or grade III-IV acute GVHD.
  • Patients taking FCR had a 48% reduced risk of chronic GVHD.

Citation:

Epperla N, Ahn K, Armand P, et al. Fludarabine and busulfan versus fludarabine, cyclophosphamide and rituximab as reduced-intensity conditioning for allogeneic transplantation in follicular lymphoma. [Published online ahead of print October 13, 2017]. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2017.10.011.